Related Experiment Video

Updated: Jul 9, 2026

Comet Assay to Quantify DNA Damage in FLT3 Mutant-expressing 32D Cells after Exposure to Type I and Type II FLT3 Inhibitors
04:36

Comet Assay to Quantify DNA Damage in FLT3 Mutant-expressing 32D Cells after Exposure to Type I and Type II FLT3 Inhibitors

Published on: October 17, 2025

Medicinal Insights Into FLT3 Inhibitors as Anticancer Agents: Current Status and Future Direction

Ankush Kumar1, Pallvi Kumari2, Keshav Raj Paudel3

  • 1Chitkara College of Pharmacy, Chitkara University Rajpura, Punjab, India.

Archiv Der Pharmazie
|July 8, 2026
PubMed

Insights

FMS-like tyrosine kinase 3 (FLT3) inhibitors show promise for acute myeloid leukemia (AML). New therapies target FLT3 mutations, improving outcomes, but resistance remains a challenge.

Area of Science:

  • Oncology
  • Molecular Biology
  • Medicinal Chemistry

Background:

  • FMS-like tyrosine kinase 3 (FLT3) is crucial for hematopoietic stem cell function.
  • Mutated FLT3, particularly internal tandem duplications (ITD) and tyrosine kinase domain (TKD) mutations, drives acute myeloid leukemia (AML) pathogenesis.
  • FLT3 signaling pathways include RAS/MAPK, PI3K/AKT, and STAT5.

Purpose of the Study:

  • To review recent advancements in FLT3-targeted therapies for AML.
  • To explore diverse chemical scaffolds and structure-activity relationships of FLT3 inhibitors.
  • To discuss challenges like resistance and future directions in FLT3-targeted treatment.

Main Methods:

  • Comprehensive literature review of FLT3 inhibitors and their clinical applications.
  • Analysis of structure-activity relationships (SAR) for various chemical scaffolds.
  • Inclusion of molecular docking studies and computational insights.

Main Results:

  • Second-generation FLT3 inhibitors like gilteritinib and quizartinib demonstrate improved efficacy and selectivity.
  • Quizartinib received FDA approval in 2023 for FLT3-ITD-positive AML.
  • Ongoing trials explore novel compounds and combination regimens, showing enhanced remission rates.

Conclusions:

  • FLT3-targeted therapies have significantly advanced AML treatment, with ongoing research into novel inhibitors and combinations.
  • Overcoming resistance mechanisms, including secondary mutations and pathway activation, is critical for durable responses.
  • Future strategies involve structure-guided design, rational combinations, and expanding FLT3 inhibitor applications to other malignancies.
Keywords:
AMLFLT3 inhibitorsSARcancertyrosine kinase

More Related Videos

Experimental Melanoma Immunotherapy Model Using Tumor Vaccination with a Hematopoietic Cytokine09:15

Experimental Melanoma Immunotherapy Model Using Tumor Vaccination with a Hematopoietic Cytokine

Published on: February 24, 2023

Related Concept Videos

Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase01:11

Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase

Genetic polymorphisms in drug targets have emerged as critical determinants of interindividual variability in drug response and toxicity. Pharmacogenomic investigations increasingly focus on identifying these variations to personalize and optimize therapeutic interventions. A drug target may be a receptor, enzyme, or signaling protein involved in pharmacologic responses or disease-related pathways. While early pharmacogenetic studies focused primarily on drug metabolism, current research...
Combination Therapies and Personalized Medicine02:50

Combination Therapies and Personalized Medicine

Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
Tumor Immunotherapy01:27

Tumor Immunotherapy

Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.
Mitogens and the Cell Cycle02:38

Mitogens and the Cell Cycle

Mitogens and their receptors play a crucial role in controlling the progression of the cell cycle. However, the loss of mitogenic control over cell division leads to tumor formation. Therefore, mitogens and mitogen receptors play an important role in cancer research. For instance, the epidermal growth factor (EGF) - a type of mitogen and its transmembrane receptor (EGFR), decides the fate of the cell's proliferation. When EGF binds to EGFR, a member of the ErbB family of tyrosine kinase...